Specialist Updates 
Cardiology

First-in-class drug ‘effective’ in hypertrophic cardiomyopathy

The results show the benefit of disease-targeted therapy, researchers say
Medicom Staff writer
0
2 September 2020
Save
Please login to bookmark Close

AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.

Mavacamten, a first-in-class cardiac myosin inhibitor, improves a range of outcomes in patients with obstructive hypertrophic cardiomyopathy, trial results show.

Results of the EXPLORER-HCM trial, presented at the European Society of Cardiology’s virtual congress (ESC 2020) this week compared outcomes of 123 people randomised to mavacamten (starting at 5mg) with 128 randomised to placebo over 30 weeks.

All participants had hypertrophic cardiomyopathy with a left ventricular outflow tract (LVOT) obstruction gradient of 50mmHg or more and were of New York Heart Association (NYHA) functional class II-III.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .